Better Health for All

Century Therapeutics' core business is developing iPSC-derived cell therapies for severe diseases like cancer, autoimmune conditions, and Type 1 diabetes.

" All programs are focused on delivering transformative health benefits, with CNTY-813 described as a potentially curative therapy for Type 1 Diabetes. " The company has invested significantly in health innovation, securing $135 million and $60 million in private placement financing, and acquiring Clade Therapeutics for $35 million upfront, all to advance its iPSC-derived cell therapy pipeline. " The company's products are designed to target underserved patient populations, including the 9 million people worldwide affected by Type 1 Diabetes and those with moderate to severe autoimmune diseases. " However, the company's risk transparency is limited to internal oversight and a forward-looking statement disclaimer, lacking comprehensive public data on risks and benefits. " While the company has a Code of Conduct, it does not provide specific details on health data protection or ethical conduct beyond general compliance. " The company's patent flexibility is limited to a non-exclusive license for reprogramming human somatic cells to iPSCs in cancer immunotherapeutics, with no broader frameworks for global health needs. " Support for healthcare workforce and preventative health measures are mentioned as internal commitments or potential outcomes of therapies, but lack specific program details or expenditure. "

Fair Money & Economic Opportunity

Century Therapeutics, Inc. is a biotechnology company focused on developing cell therapies, not a financial institution.

The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its core business model. While the company's therapies may address underserved medical markets or aim for affordability and accessibility, these do not align with the financial services definitions of the KPIs.

Fair Pay & Worker Respect

Century Therapeutics has an overall employee rating of 4.2 out of 5 stars, and 92% of employees would recommend working at the company.

However, the company plans a 51% workforce reduction by the third quarter of 2025, impacting approximately 77 out of 150 employees. This reduction is expected to incur $3.7 million in severance and other employee termination-related costs. The Chief Financial Officer departed on July 11, 2025.

Kind to Animals

Century Therapeutics, Inc. (IPSC.US) conducts animal studies as part of its nonclinical tests for product safety and activity, adhering to Good Laboratory Practices and requirements for the humane use of laboratory animals.

The company has an 'Animal Use and Welfare Statement' and states a commitment to the ethical and humane treatment of animals in research. However, it does not provide specific data on the number of animals used annually, only that animal studies are part of the development process. The company operates within a regulatory environment where the FDA Modernization Act 2.0 (2022) allows for the use of alternative testing methods, and the FDA announced a plan in April 2025 to phase out mandatory animal testing for certain drugs. There is no evidence that IPSC.US actively engages in animal welfare policy improvement or advocacy for higher standards.

Safe & Smart Tech

The company retains comments and metadata indefinitely, and login cookies for two days, screen options cookies for one year, and article edit cookies for one day.

This indicates limited data minimization practices and retention periods, aligning with collecting data 'just in case' it might be useful. Users have good privacy controls, including the ability to see, edit, or delete their personal information (except username), request an exported file of their personal data, and request erasure of personal data (excluding data kept for administrative, legal, or security purposes). The company states that acquired companies have been and are being researched, developed, tested, manufactured, packaged, labeled, stored, and handled in compliance with all applicable requirements under the Federal Food, Drug, and Cosmetic Act, U.S. Public Health Service Act, FDA guidance, and analogous state and non-U.S. Legal Requirements, including Good Manufacturing Practice, Good Laboratory Practices, and Good Clinical Practices.